Background: Antihypertensive medication decreases risk of cardiovascular disease (CVD) events in adults with hypertension. Although black adults have higher prevalence of hypertension and worse CVD outcomes compared with whites, limited attention has been given to the cost-effectiveness of antihypertensive medication for blacks.
H ypertension, diagnosed as a systolic blood pressure (SBP)Z140 mm Hg or diastolic blood pressure (DBP) Z90 mm Hg among individuals not taking antihypertensive medication, is common in the United States, affecting almost one third of adults. [1] [2] [3] Hypertension is associated with increased risk of stroke and coronary heart disease (CHD), chronic kidney disease (CKD), and end-stage renal disease (ESRD), and an annual cost to the US health care system of B$22 billion. 4, 5 Antihypertensive medication can lower blood pressure (BP) and therefore mitigate negative consequences of hypertension. 1 For instance, studies suggest that even modest BP reductions can lower the 5-year risk of stroke and myocardial infarction (MI) by 41% and 22%, respectively. 2, 6 Despite the benefits of antihypertensive medication, data show that among US adults diagnosed with hypertension, B25% were not treated using antihypertensive medication. 7 In addition to being effective for treatment of hypertension, antihypertensive medication has also been found to be cost-effective, 5, [8] [9] [10] and cost-saving. 11 Cost-effectiveness analysis is a useful tool for decision-making and resource allocation, allowing decision-makers to identify the lowest cost and most clinically beneficial treatments. 9, 12 However, studies on the cost-effectiveness of antihypertensive medication primarily focus on treatment for whites and the general population rather than blacks. 8 This is of concern for several reasons. Black adults have the highest prevalence of hypertension in the United States, are less likely to have controlled hypertension, and experience higher death rates from hypertension-related events such as stroke, CHD, and heart failure (HF) compared with whites. 1, 13, 14 Given the undertreatment of hypertension among the US population, disparities in hypertension control and outcomes between black and white US adults, and the potential opportunity for improvements in outcomes associated with antihypertensive medication treatment, the purpose of this paper is to assess the cost-effectiveness of antihypertensive medication treatment in white and black men and women using a State Transition Model (STM). 15 We use data from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study to derive race and sex-specific model inputs for the STM. REGARDS oversampled black adults to investigate racial differences in stroke, 16 therefore the data were particularly well suited for use in this analysis. This study will be of interest to insurance providers, health care organizations, policymakers, and researchers seeking to address disparities in quality of care and more efficiently use health care resources.
METHODS

Population
The simulation study population was modeled using demographic and clinical data from REGARDS study participants. REGARDS is an ongoing observational study of risk factors associated with stroke and has enrolled 30,239 participants. Blacks were oversampled to better understand the stroke risk differences between blacks and whites. The study design, recruitment, and data collection procedures used in REGARDS have been described in detail previously. 16 In brief, participants aged 45 years and older were recruited between 2003 and 2007. Data on cardiovascular disease (CVD) history, sociodemographic, lifestyle, and psychosocial characteristics were collected using a computer-assisted telephone interview. Physical and physiological measures and biological samples were collected during a subsequent inhome visit along with written informed consent. SBP and DBP were measured twice, 30 seconds apart, after the participant had been seated for 5 minutes. The average of these measurements was recorded. 16 Hypertension was defined as an average SBPZ140 mm Hg, average DBPZ90 mm Hg, or self-reported use of antihypertensive medication. Number of antihypertensive medications was determined from a pill bottle review. The current study sample was limited to RE-GARDS participants who were identified as taking antihypertensive medication (n = 18,036). The University of Alabama at Birmingham institutional review board approved this study.
Treatment Strategies
We compare antihypertensive medication treatment with a simulated no-treatment strategy. We utilized demographic and clinical characteristics of REGARDS participants who were taking antihypertensive medication at baseline to derive the simulation population for the treatment group. Participants were classified based on the race and sex likelihood that they would be treated with 1, 2, 3, or Z4 antihypertensive medications. Antihypertensive medication is primarily utilized to lower BP and we assumed BP would be the only difference between the treatment and notreatment strategies. Therefore, to create a no-treatment comparison group, we extrapolated SBP from the treated group. We projected that for every medication a participant was prescribed, their SBP would be lowered 9 mm Hg. 17 To estimate the SBP of a participant in the simulated no-treatment group who was not treated but should have been treated using 1 medication, their SBP would be 9 mm Hg higher than an individual who was taking 1 antihypertensive medication; 18 mm Hg higher if they should have been treated with 2 antihypertensive medications, and so forth.
Model
The STM assessed the cost-effectiveness of antihypertensive medication treatment versus no-treatment for white men, white women, black men, and black women (Fig. 1) . We included costs of antihypertensive medications and adverse events, and utilities of health states measured in quality-adjusted life-years (QALYs) in the model (Table 1) . We considered 7 classes of antihypertensive medication in the model; diuretic, beta blocker, angiotensin-converting enzyme inhibitor, calcium channel blocker, aldosterone receptor antagonist, alpha blocker, and angiotensin receptor blocker. Participants entered the STM at age 45 and remained in the model until they died or reached 100 years of age. 15 
Data and Model Input Sources
We utilized REGARDS data for several model inputs including the distribution of the number of antihypertensive medications participants were prescribed by race and sex in the treatment strategy (Table 2 ). This distribution was used to determine the corresponding number which participants should have been treated with for the no-treatment strategy. REGARDS data were also used to determine 10-year Framingham Stroke and CHD risk scores (Supplemental Methods, Supplemental Digital Content 1, http://links.lww.com/MLR/B367), converted to yearly event probabilities. 35 Transition probabilities for stroke and CHD were then assigned to model participants based on age (45-64, 65-74, 75 y of age and above), race, sex, and number of antihypertensive medications prescribed (1, 2, 3, Z4 medications) (Supplemental Methods, Supplemental Digital Content 1, http://links.lww.com/MLR/B367).
Similar to other cost-effectiveness models, [8] [9] [10] 32, 36 we used published literature for several model inputs including transition probabilities for CKD, ESRD, HF, and mortality following events, as well as differences in these transition FIGURE 1. Simplified State Transition Model structure comparing the cost-effectiveness of hypertension treatment with antihypertensive medication versus no-treatment. A, A black women entering a decision tree to determine either treatment or notreatment. Subsequently, the number of medications taken, for the treatment scenario, or the number of medications that should have been taken, for the no-treatment scenario, are assigned (supplemental methods). B, The Markov node structure for the "treatment with 1 antihypertensive medication" branch. Once a participant suffers an event and enters a new health state, they remain in that health state until suffering another event or death. All Markov nodes for treatment with 2, 3, or Z4 antihypertensive medications as well as for the no-treatment branches are identical to the "treatment with 1" medication node. CKD indicates chronic kidney disease; ESRD, end-stage renal disease; HF, heart failure; HTN, hypertension; MI, myocardial infarction; QALYs, quality-adjusted life-years; RX, prescription; TX, treatment.
probabilities by race and sex (Table 1) . Data on renal events and estimates of excess risk of CKD and ESRD for blacks compared with whites were obtained from the United States Renal Data System (USRDS) and MarketScan data. 22, 37 Race-based mortality from other causes not included in the model was estimated using the National Center for Health Statistics mortality rate tables. 24 We also used published literature to determine QALY ratings associated with health states (Table 1 ). All future utilities were discounted using a 3% rate. 38 
Costs
We included drug costs and costs of adverse events and health states in the model. Antihypertensive treatment costs are based on the cost and number of antihypertensive medications prescribed (Supplemental Methods, Supplemental Digital Content 1, http://links.lww.com/MLR/B367). We used Medicare claims data from 2012 to estimate the cost of antihypertensive medication (Table 1) . Costs of events and health states were determined using published estimates (Table 1) . We used a third-party payer perspective in the estimation of health care-related costs. All costs were adjusted to 2012 US dollars using the Consumer Price Index and future costs were discounted using a 3% rate. 38, 39 Postevent Health States Participants started in a "no-event" health state and subsequently transitioned to "postevent" states once an 
Sensitivity Analysis
We conducted 1-way sensitivity analyses, 40, 41 varying parameters by ± 50%. We considered a parameter sensitive if varying it resulted in a cost-effectiveness ratio that was double the baseline value. 36 In addition, we conducted probabilistic sensitivity analysis using triangle distributions randomly sampled 1000 times for costs and QALYs varied by ± 50%. We also simulated a worst-case scenario analyses by varying all costs and QALYs by ± 50% in favor of notreatment.
RESULTS
At baseline, 18,036 REGARDS participants were taking antihypertensive medication; 4536 white women, 5469 black women, 4882 white men, and 3149 black men (Table 2). Black participants had the highest prevalence of smoking and diabetes. White women were most likely to be treated with only 1 antihypertensive medication at baseline (43.8%) and had the lowest average SBP (126.1 mm Hg) while being treated with 1 medication compared with other race and sex groups ( Table 2) . Among participants taking Z4 or more antihypertensive medications, black men had the highest prevalence of being treated with this number of medications at baseline (10.3%) and had the highest average SBP (136.6 mm Hg) while receiving this treatment compared with other race and genders. Table 3 shows 1-year probabilities for stroke and CHD by race, sex, age, and number of antihypertensive medications prescribed among treated and untreated REGARDS participants. Among both the treatment and no-treatment strategies, white women entered the STM with the lowest 1-year stroke and CHD risks. For instance, the 1-year probability for stroke events among white women in the treatment strategy ranged from 0.4% on 1 medication to 0.7% on Z4 medications at baseline for ages . Black men had the highest baseline 1-year stroke and CHD risk in both the treatment and no-treatment strategies. For 10-year Framingham stroke and CHD risk among these subgroups, refer Afib was defined by self-report of physician diagnosis or electrocardiogram evidence. 33 LVH was identified by electrocardiogram evidence using the Sokolow-Lyon criteria. 33, 34 Afib indicates atrial fibrillation; HDL, high-density lipoprotein; LVH, left ventricular hypertrophy; SBP, systolic blood pressure.
to Supplemental Table 2 , Supplemental Digital Content 1, http://links.lww.com/MLR/B367. Table 4 shows lifetime costs and QALYS for the treatment scenario compared with no-treatment. Lifetime costs in the treatment scenario were lower compared with notreatment for all race and sex categories. White women who were treated with antihypertensive medication had the lowest lifetime health care costs ($45,318). However, the incremental costs for treated black women were the most costsaving among all race and sex groups, costing $10,249 less compared with the no-treatment scenario. In all cases, treatment resulted in a gain of QALYs for treated participants compared with no-treatment. Black women in the treatment group had the largest increase in QALYs gained compared with those in the no-treatment group (1.79 QALYs).
The model was not sensitive to changes in cost or QALY parameters during 1-way sensitivity analyses. Antihypertensive treatment remained cost-saving and always dominated no-treatment with lower costs and more QALYs for all race and sex groups (Supplemental Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/MLR/B367). Costs of CHD, CKD, and HF had the largest influence on cost-effectiveness ratios in sensitivity analyses. In probabilistic sensitivity analysis simulations, treatment remained CHD consisted of nonfatal MI and fatal CHD. *Number of antihypertensive medications for participants receiving no-treatment represent the number they should have been receiving. Average SBP was estimated for this group as described in the Treatment strategies section of the Methods section.
CHD indicates coronary heart disease; MI, myocardial infarction; SBP, systolic blood pressure. cost-saving and increased the number of QALYs, and treatment of black participants resulted in more savings and QALYs gained in comparison with whites (Supplemental Fig. 2 , Supplemental Digital Content 1, http://links.lww. com/MLR/B367). In the worst-case scenario analyses, all race and sex combinations of the treatment strategy remained cost-saving and dominated the no-treatment strategy (Supplemental Table 3 , Supplemental Digital Content 1, http:// links.lww.com/MLR/B367).
DISCUSSION
The main finding of the current study is that antihypertensive treatment is cost-saving and produced more QALYs compared with no-treatment for all race and sex groups, particularly among black adults. There are several potential explanations for this finding. First, treatment has been shown to be effective in reducing BP and lowering the risk of CVD events across the spectrum of BP levels. 2, 6 Lowering the risk of CVD leads to lower yearly health care expenditures and more QALYs. Second, antihypertensive treatment is relatively inexpensive and generic versions of most drugs are currently available. 42 The results of this study are similar to Moran and colleagues who report that antihypertensive medication treatment, following guidelines of the 2014 recommendations of the Eighth Joint National Committee, would result in cost-savings and increased QALYs among men between 45 and 75 years of age with either stage 1 hypertension (SBP between 140 and 159 mm Hg), stage 1 hypertension and diabetes or CKD, and stage 2 hypertension (SBPZ160 mm Hg), and among women between 45 and 75 years of age with stage 2 hypertension. 11 Although our results were comparable with Moran and colleagues for men and women, our model allowed us to not only assess the cost-effectiveness of treatment by sex, but also by race, and treatment of blacks resulted in the most cost-savings. Similar to the results of this study, Tasosa and colleagues found that treatment of blacks was more cost-effective compared with treatment of whites. Using an age group comparable with our own, they report cost-effectiveness ratios for antihypertensive treatment of $23,148/QALY for blacks and $35,213/QALY for the general population, but unlike our results, Tasosa and colleagues did not find treatment to be cost-saving. However, it is difficult to compare the 2 studies as Tasosa and colleagues examined a diabetic population and also assessed treatment of hyperlipidemia and hyperglycemia, in addition to hypertension. This highlights a shortcoming of the current literature on the costeffectiveness of antihypertensive medication treatment: there is very little comparability between studies. [8] [9] [10] One potential explanation for the finding that treatment of blacks resulted in the most cost-savings is that white individuals, on average, are healthier than blacks. 43 For example, at baseline, white individuals had lower BP compared with blacks. Therefore, in the current model, blacks who were not treated with antihypertensive medication entered higher categories of CVD risk as they progressed through the model compared with whites and thus experienced worse outcomes. However, while antihypertensive treatment of blacks was more cost-saving compared with whites, whites had lower average health care costs overall. This is likely also due to lower SBP, the need for less medication, and better general health at baseline among whites compared with blacks.
The observation that whites had lower SBP than blacks at baseline could be attributed to better general health among whites, or this finding could be due to other factors. First, whites may respond better to antihypertensive medication treatment than blacks. For instance, Cushman and colleagues reported that compared with whites, blacks had worse hypertension control following treatment with antihypertensive medication and this difference could not be explained by baseline demographic or clinical differences. 43 Also, lower rates of control are observed even though blacks are prescribed more antihypertensive medication on an average compared with whites. 44 Another possible explanation for lower SBP in whites compared with blacks is that whites have better adherence to antihypertensive medication. 45, 46 Poor adherence can result in less effective BP control, exposing individuals to an increased risk of CVD events. 44 Improving antihypertensive medication adherence among blacks could result in additional cost-savings and improvements in quality of life. Several strategies have been shown to be effective in improving adherence among black adults, including reductions in copayments for antihypertensive medication and building trust between physicians and patients through improved communication and/or race concordant physician/patient pairings. [47] [48] [49] [50] In addition to medication adherence, lifestyle modification has been recommended by the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure to improve hypertension control in black adults. 51 Although we did not consider lifestyle modification in the current model, it may provide a complement to antihypertensive medication. For instance, in a systematic review of intervention studies focused on lowering BP through improvements in physical activity, diet, and weight reduction among black adults in the United States, health behavior modification was associated with lower BP levels and improved BP control. 52 International studies have demonstrated the cost-effectiveness of a combination of antihypertensive medication treatment and lifestyle interventions. 53 Results remained consistent during 1-way sensitivity analyses. In all cases, treatment dominated no-treatment and remained cost-saving in the analyses. Although researchers argue that 1-way sensitivity analysis is sufficient to deal with uncertainty in model estimates, 41 we also conducted probabilistic sensitivity analysis and treatment remained cost-saving. Even using the most pessimistic values for all costs and the most optimistic values for QALYs during the worst-case scenario analyses, the model results remained robust with treatment resulting in cost-savings and increased QALYs.
The current study has several strengths. First, we use race and sex-specific model inputs derived from the RE-GARDS study and previously validated published literature sources. Second, the results of the study were robust, remaining consistent in sensitivity analyses. In addition, we included multiple CVD and renal events associated with hypertension in the analyses, and allowed the STM to account for increased risk of suffering future events following stroke, MI, HF, CKD, and ESRD. However, this study should be interpreted in the context of its limitations. One such limitation is related to stroke and CHD risk calculation. Although Framingham stroke and CHD estimates have been validated and previously used in cost-effectiveness studies of antihypertensive treatment, McClure and colleagues find that Framingham stroke risk equations overestimate stroke risk compared with observed strokes in the REGARDS dataset. Therefore it is possible that our model inflates the event rate for both those receiving treatment and those with no-treatment, potentially overestimating the benefits of treatment. 33 The recent American College of Cardiology/American Heart Association Pooled Cohort risk equations may have provided a more accurate estimate of CVD risk in both black and white adults in our study as they were derived from a more racially diverse dataset compared with the Framingham Stroke and CHD risk equations. 54 However, the Pooled Cohort equations also overestimate predicted versus observed risk of CVD in REGARDS, 55 and do not estimate stroke and CHD risk separately, but rather the risk of either a stroke or CHD event. There are important differences in the incidence, costs, and disutilities of stroke and CHD, therefore, we did not use the Pooled Cohorts risk equations in this analysis. Finally, because our model was not designed to determine comparative effectiveness of medications, we were unable to provide comparisons of the cost-effectiveness of different antihypertensive medication classes.
CONCLUSIONS
In this study, treatment of hypertension with antihypertensive medication was cost-saving for all race and sex groups considered in the model. Treatment among black adults resulted in the most cost-savings and QALYs gained. Given the findings of this study, undertreatment of hypertension potentially represents a lost opportunity for lowering health care costs while improving quality of life for both black and white adults with hypertension. Also, increasing treatment rates and adherence among black adults may allow third-party payers and health care providers to align themselves with the National Academies of the Sciences-Health and Medicine Division's commitment to addressing racial disparities in care. 56 
